Kuros Biosciences raises €19.7M Growth round
18 November 2013· Schlieren, Switzerland· health, orthobiologics, biotech, materials, b2b, deep_hardware
The additional capital from this offering supports the development activities for its lead program, CYT003, which was on track for core data release in April 2014.
Investors
LeadAbingworth
Also participating
venBioAmgenAisling CapitalInternational institutional investorsother shareholders
About Kuros Biosciences
Stage
Growth
Headquarters
Schlieren, Switzerland
Founded
2000
Team Size
51–200
Sectors
healthorthobiologicsbiotechmaterialsb2bdeep_hardware